In 1994, the first case reports of colonic strictures (now referred to as fibrosing colonopathy) in children with cystic fibrosis appeared in the medical literature.1-5 The initial case reports described patients who presented with intestinal obstruction and required surgical resection of a thickened and narrowed area of colon.' The only aspect of these children's management that had changed was a switch to new 'high strength' pancreatic enzyme preparations about 12 months previously. It was suggested that use of these preparation may be associated with this condition. Abdominal complaints occur frequently in cystic fibrosis; for example the incidence of Crohn's disease has been reported to be 17 times higher than the general population.6 It was not clear initially whether these cases represented variations of the normal pathology reported in cystic fibrosis, or a new entity. In some instances, the clinical and radiological features were suggestive of Crohn's disease, or an inflammatory colitis, but the histological findings were strikingly different. It is the pathological findings (described below), not reported previously in cystic fibrosis, which have characterised this condition. I will attempt to review the clinical, radiological, and histological features of this condition and discuss the current evidence on aetiology. The decision about when to operate may not be straightforward, except in children who have large bowel obstruction. Some children have been operated on because of intractable diarrhoea, faecal incontinence, anorexia, and weight loss.4 5 In a number of children who presented with evidence of extensive involvement of the colon, defunctioning ileostomies have been performed in the hope that by diverting faeces from the colon some of the changes may resolve and a more limited resection may subsequently be undertaken. The experience in some of these cases has been that rather than improving, the narrowing has progressed and become more extensive,7 rendering subsequent surgery more difficult. I am aware of a number of children who have presented with diffuse involvement of the colon, and in whom resection or ileostomy has been avoided. These children have remained well on conservative management. It would therefore seem wise to manage these children conservatively where possible, but with very careful clinical monitoring and annual ultrasound to assess bowel wall thickness. 17 Shortly after the first reports of fibrosing colonopathy, in the UK, epidemiological studies were designed firstly to establish the incidence of this condition in the cystic fibrosis population in the country, secondly to determine if it was a new entity, and finally to identify factors with which it was associated.14 A cohort evaluation was initiated to address the first two of these aims. Details were requested of all cystic fibrosis patients who had undergone surgery in between 1984 and 1994. Where small or large bowel had been resected or biopsied, the histological sections were reviewed. It was well recognised that a number of cases had presented with clinical and radiological features of fibrosing colonopathy, but had not required surgery and histological material was not therefore available. Because the diagnosis in these cases was less precise, it was decided not to include them in the casecontrol study. Fourteen cases of fibrosing colonopathy were identified, the first occurring in April 1993. Twelve were boys and six had received some or all of their care in Liverpool. A nested case-control study was then undertaken, where each case was matched by date of birth with four controls taken from the UK cystic fibrosis survey. The case-control studied identified an association between fibrosing colonopathy and use of high strength pancreatic enzyme preparations, but not the use of low strength preparations. The association with high strength preparations was dose related, temporally credible, and biologically plausible. Not all high strength products were, however, found to be associated. Two similar products, Pancrease HL (Cilag) and Nutrizym 22 (Merck) were found to be associated with fibrosing colonopathy, but Creon 25000 (Duphar) was not.
Radiological features
The study also demonstrated that cases were more likely than controls to have taken laxatives in the 12 months before surgery. A possible explanation for this was that when patients with fibrosing colonopathy initially presented they had abdominal pain. Some were thought to have distal intestinal obstruction syndrome and were therefore treated with laxatives. This illustrates the difficulty of inferring causality on the basis of an association demonstrated in an observational case-control study.
There were two main hypotheses generated from this case-control study. The first was that the disorder is due to one of the active constituents of pancreatic enzyme preparations. The use of high strength enzyme preparations would enable much larger doses of such an active constituent to be delivered to the colon. If this hypothesis were correct, this condition may occur if sufficiently large doses of low strength preparations were taken. An alternative hypothesis is that the disorder is due to an excipient present in the enteric coating of the microencapsulated preparations, which damages the colon in a dose dependent manner. Creon 35000 is formulated as microspheres, which are heterogenous in size; Pancrease HL and Nutrizym 22 are formulated as minitablets which are of uniform size. Eudragit-L, one of the components of the minitablet coating, is a copolymer based on methylacrylic acid and ethyl acrylate. These compounds have been shown to have a toxic effect on the gut of experimental animals.18 19 It has been suggested that the methylacrylic acid copolymer present in the enteric coating of some preparations may be causal factor in the aetiology of fibrosing colonopathy.20 This hypothesis would explain the association with high strength preparations, and the difference in association between different high strength products. Indirect evidence in support of the second hypothesis has come from two further observations. The first is that two, histologically confirmed, cases of fibrosing colonopathy have been described in young children treated with the low strength preparation Nutrizym GR (Merck).20 21 
